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Abstract
Altered DNA methylation of tumor suppressor gene promoters plays a role in human carcinogenesis and DNA
methyltransferases (DNMTs) are responsible for it. This study aimed to determine aberrant expression of DNMT1, DNMT3a,
and DNMT3b in benign and malignant ovarian tumor tissues for their association with clinicopathological significance and
prognostic value. A total of 142 ovarian cancers and 44 benign ovarian tumors were recruited for immunohistochemical
analysis of their expression. The data showed that expression of DNMT1, DNMT3a, and DNMT3b was observed in 76 (53.5%),
92 (64.8%) and 79 (55.6%) of 142 cases of ovarian cancer tissues, respectively. Of the serious tumors, DNMT3a protein
expression was significantly higher than that in benign tumor samples (P=0.001); DNMT3b was marginally significant down
regulated in ovarian cancers compared to that of the benign tumors (P=0.054); DNMT1 expression has no statistical
difference between ovarian cancers and benign tumor tissues (P=0.837). Of the mucious tumors, the expression of
DNMT3a, DNMT3b, and DNMT1 was not different between malignant and benign tumors. Moreover, DNMT1 expression was
associated with DNMT3b expression (P=0.020, r=0.195). DNMT1 expression was associated with age of the patients,
menopause status, and tumor localization, while DNMT3a expression was associated with histological types and serum
CA125 levels and DNMT3b expression was associated with lymph node metastasis. In addition, patients with DNMT1 or
DNMT3b expression had a trend of better survival than those with negative expression. Co-expression of DNMT1 and
DNMT3b was significantly associated with better overall survival (P=0.014). The data from this study provided the first
evidence for differential expression of DNMTs proteins in ovarian cancer tissues and their associations with
clinicopathological and survival data in sporadic ovarian cancer patients.
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Introduction
Epigenetic alteration of the genomic DNA refers to functionally
relevant modifications of the genome that affects gene expression
but do not involve a change in the nucleotide sequence, which
plays an important role in human carcinogenesis. Such modifica-
tions include DNA methylation, chromatin remodeling and
histone variants, and the epigenetic function of non-coding RNA
[1]. Among these, DNA methylation is a covalent modification of
DNA that plays an important role in setting gene expression
programs during development [2]. Nevertheless, abnormal DNA
methylation does also play an important role in human cancer
development, and most cancer cells show a global hypomethyla-
tion of the genome that induces abnormal expression of genes but
a local hypermethylation that silences tumor suppressor genes
[1,3]. In mammals, DNA methylation is established and main-
tained mainly by three DNA methyltransferases (DNMTs), namely
DNMT1, DNMT3a, and DNMT3b. The preferred target of
DNMT1 is hemi-methylated DNA [4,5] and this protein functions
as a ‘‘maintenance’’ methyltransferase and the primary enzyme
responsible for copying methylation patterns after DNA replica-
tion. It localizes to replication foci and interacts with proliferation
cell nuclear antigen (PCNA) [6]. In contrast, DNMT3a and
DNMT3b are essential for early embryonic development and
responsible for de novo methylation [7]. Overexpression of these
three DNMTs has been reported in various malignancies and
associated with poor survival of different cancers, including lung,
liver, and cervical cancers and lymphomas
[8,9,10,11,12,13,14,15,16,17,18]. Unlike cancer-associated gene
mutations, amplifications, and deletions, DNA methylation is
potentially reversible. Thus, DNMTs have been investigated as
a target for re-expression of tumor suppressor genes and reversal of
malignant phenotypes in different malignancies [19]. Most
recently, antisense oligonucleotides targeting DNMT genes, for
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has now entered into clinical phase I and phase II studies [20,21].
Epithelial ovarian cancer is the sixth leading cancer in women
worldwide and the second most common gynecologic cancer,
accounting for approximately 4% of all female cancers [22,23].
Due to lacking early warning signs and effective screening tools,
majority of patients present with late stages of the disease [24].
Epithelial ovarian cancer is the most lethal gynecologic malignan-
cy and the five-year survival rate is below 25% for patients
diagnosed with stage III - IV diseases [25,26]. Similar to other
malignancies, aberrant DNA methylation on CpG islands is also
an important mechanism for ovarian cancer development. Pre-
clinical studies indicated that de-methylation agents were able to
reverse resistance of ovarian cancer cells to platinum [27,28],
leading to using DNMT inhibitors in clinical trials of ovarian
cancers [29,30,31,32]. However, there are no data available on
study of DNMT proteins in ovarian cancer tissues, although two
previous studies have reported the expression of DNMT mRNA in
ovarian cancer cell lines and small tissue samples [33,34]. In this
study, we collected 142 cases of epithelial ovarian carcinoma
samples and 44 cases of benign ovarian tumors for detection of
DNMT1, DNMT3a, and DNMT3b protein expressions in order
to determine the role of DNMT proteins in ovarian cancer and
clinical significance.
Results
Patient Characteristics
In this study, we recruited tissue samples from 186 ovarian
tumor samples for evaluation of DNMTs protein expression. The
clinicopathological data from the patients are shown in Table 1.
Briefly, the mean age of the patients at surgery was 53 years
(ranging from 20 to 74 years). 27 (23.3%) patients had lymph
node-metastasized disease at the time of surgery and 110 (77.5%)
patients had serous carcinoma as the main histological diagnosis,
followed by mucinous carcinoma (8.5%), clear cell carcinoma
(,5.6%), and undifferentiated carcinoma (,5.6%). The serum
levels of CA125, CA199, and CEA were elevated before surgery
but none of the patients received any neo-adjuvant chemotherapy.
Follow-up data were available for 85 patients. The mean and
median overall survivals (OS) were 56.1 and 41.0 months,
respectively, with a 95% confidence interval of 45.3 to 66.9 and
33.2 to 48.8 months. The mean and median disease-free survivals
(DFS) were 46.6 and 26.0 months, respectively, with a 95%
confidence interval of 36.4 to 56.9 and 14.6 to 37.4 months. In the
44 benign tumors, 31 were serous and 13 mucinous.
Differential Expression of DNMT Proteins in Malignant
and Benign Ovarian Tumors
Differential expression of DNMT proteins in malignant and
benign ovarian tumors according to histological type is summa-
rized in Table 2. In particular, the expression of DNMT3a protein
was significantly higher than that of benign tumor tissues (Mann-
Whitney U-test test, P=0.001; Table 2), but the difference was not
observed in mucious tumors (Mann-Whitney U-test test,
P=0.813; Table 2). While DNMT3b protein was detected in 64
(58.2%) of the 110 serous cancer cases and 22 (71.0%) of the 31
serous benign tumors, indicating that DNMT3b expression in
ovarian cancers was lower but not significantly than that of benign
tumors (Mann-Whitney U-test test, P=0.054; Table 2), but the
difference was not observed in mucious tumors (Mann-Whitney
U-test test, P=0.536; Table 2). In contrast, the expression of
DNMT1 protein was not significantly different between in ovarian
cancer and benign tumor samples either in serious or in mucious
tumors (Mann-Whitney U-test test, serous: P=0.837; mucious:
P=0.315 Table 2). Representative expression patterns of immu-
nohistochemical staining of DNMTs in ovarian cancer and benign
tumor tissues were shown in Figure 1 and Figure 2 respectively.
Next, we associated expression of these three DNMT proteins in
the ovarian cancer tissues by using Spearman’s rank correlation
test. The data showed that expression of DNMT1 was significantly
associated with DNMT3b (r=0.195, P=0.020; Table 3), but not
Table 1. Patient characteristics.
Feature Categories Number %
Age, years #53 79 57.2
.53 59 42.8
unknown 4 –
Menopause state pre-menopause 45 34.6
post-menopause 85 65.4
unknown 12 –
Histological type serous 110 77.5
mucinous 12 8.5
clear cell 8 5.6
transitional 2 1.4
endometrioid 2 1.4
undifferentiated 8 5.6
Tumor size, cm #5 15 12.5
5,10 53 44.2
.10 51 43.3
unknown 23 –
FIGO stage I,II 31 24.4
III,IV 96 75.6
unknown 15 –
Nodes metastasis no 89 76.7
yes 27 23.3
unknown 26 –
Location of tumor single side 56 43.4
both sides 73 56.6
unknown 13 –
CA125, U/ml 0,35 10 10.1
35,500 40 40.4
500,1000 32 32.3
.1000 17 17.2
unknown 43 –
CA199, U/ml 0,37 67 76.1
37,100 10 11.4
.100 11 12.5
unknown 54 –
CEA, ng/ml 0,5 72 91.1
.5 7 8.9
unknown 63 –
Chemotherapy platinum-based 111 94.9
nonplatinum 3 2.6
No chemotherapy 3 2.6
unknown 25 –
doi:10.1371/journal.pone.0040024.t001
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the DNMT3a and DNMT3b proteins (r=0.152, P=0.071;
Table 3).
Association between Expression of DNMT Proteins and
Clinicopathological Parameters
After detected expression of these three DNMT proteins using
immunohistochemistry, we associated their expressions with
clinicopathological data from the patients. Our data showed that
DNMT1 expression was significantly associated with age and
menopause state of the patients and with tumor localization.
Expression of DNMT1 protein in the older (.53 years) or
postmenopausal patients was higher than that of younger patients
(Pearson Chi-Square test, P=0.028; Table 4) or premenopausal
patients (Pearson Chi-Square test, P,0.000; Table 4). Moreover,
expression of DNMT1 protein was higher in the patients whose
tumor occurred in single side than that of patients whose tumor
occurred in both sides (Pearson Chi-Square test, P=0.010;
Table 4). However, there were no significant associations present
between DNMT1 immunoreactivity and tumor size, lymph node
metastasis, clinical stage, histological type, CA125, or CA199.
Furthermore, there was a significant association between
DNMT3a and serum CA125 level (Pearson Chi-Square test,
P=0.044; Table 4). Expression of DNMT3a protein was 69.1% in
serous carcinoma, which was higher than that of mucinous
carcinoma (33.3%) and clear cell carcinoma (50%) (Fisher’s exact
test, P=0.027; Table 4). But there was no association between
DNMT3a immunoreactivity and other clinical pathological
parameters, as displayed in Table 4.
In addition, the data revealed that DNMT3b expression was
significantly associated with lymph node metastasis of ovarian
cancer (Pearson Chi-Square test, P=0.027; Table 4). Although
there is not statistically significant, expression of DNMT3b protein
appeared to be associated with high level of serum CA199
(Pearson Chi-Square test, P=0.061; Table 4).
Co-expression of DNMT1 and DNMT3a was significantly
associated with menopause state (Pearson Chi-Square test,
P=0.008; Table 4) and location of the tumor (Pearson Chi-
Square test, P=0.036; Table 4), while co-expression of DNMT1
and DNMT3b was significantly associated with menopause state
(Pearson Chi-Square test, P=0.001; Table 4) and location of the
tumor (Pearson Chi-Square test, P=0.015; Table 4). Co-
expression of DNMT1 and DNMT3b was also significantly
associated with the serum CA199 levels (Pearson Chi-Square test,
P=0.013; Table 4).
Association of DNMT Protein Expressions with Survival of
the Patients
After that, we associated expression of DNMT protein with
survival of the patients using Kaplan-Meier analysis (Figure 3).
Particularly, although it is not significantly different, patients with
DNMT expressions had a trend of improved survival than those
with negative expression, opposite of findings from previous
studies in other types of cancer [8,13,17,18,35,36]. In our samples,
DNMT1 expression marginally associated with improved OS
(P=0.084; Fig. 3A) and DFS (P=0.186; Fig. 3D); and so did
DNMT3b. Moreover, co-expression of DNMT1 and DNMT3b
was significantly associated with improved overall survival
compared to other samples (only DNMT1 or DNMT3b expres-
sion or both negative) (P=0.014, Fig. 4C). Univariate analysis of
the potential prognostic impact of clinical and histopathological
parameters identified clinical stage, location of tumor, and serum
CA125 level as significantly or marginally significantly associated
with shorter OS and DFS (Table 5).
Table 2. DNMTs expression in malignant and benign ovarian tumors.
2 + ++ +++
n n (%) n (%) n (%) n (%) PR
a,% P-value
b
serous DNMT1
Malignant 110 51 (46.4) 46 (42.6) 7 (5.5) 6 (5.5) 53.6 0.837
Benign 31 17 (54.8) 4 (12.9) 6 (19.4) 4 (12.9) 45.2
DNMT3a
Malignant 110 34 (30.9) 31 (28.2) 25 (22.7) 20 (18.2) 69.1 0.001
Benign 31 22 (71.0) 5 (16.1) 1 (32.2) 3 (9.7) 29.0
DNMT3b
Malignant 110 46 (41.8) 36 (32.7) 18 (16.4) 10 (9.1) 58.2 0.054
Benign 31 9 (29.0) 8 (25.8) 5 (16.1) 9 (29.0) 71.0
mucious DNMT1
Malignant 12 5 (41.7) 6 (50.0) 0 (0) 1 (8.3) 58.3 0.315
Benign 13 5 (38.5) 2 (15.3) 3 (23.1) 3 (23.1) 62.5
DNMT3a
Malignant 12 8 (66.7) 3 (25.0) 1 (8.3) 0 (0) 33.3 0.813
Benign 13 8 (61.5) 3 (23.1) 2 (15.4) 0 (0) 38.5
DNMT3b
Malignant 12 5 (41.7) 5 (41.7) 0 (0) 2 (16.6) 58.3 0.536
Benign 13 7 (53.8) 4 (30.8) 2 (15.4) 0 (0) 46.2
2 negative; + weak; ++ moderate; +++ strong staining;
aPR, positive rate.
bP-value obtained from Mann-Whitney U-test test.
doi:10.1371/journal.pone.0040024.t002
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stage, tumor size, location of neoplasia, DNMT1 and DNMT3b
co-expression revealed that only clinical stage (OS, P=0.022,
RR=6.977, 95% CI: 1.322,36.822; DFS, P=0.026,
RR=4.686, 95% CI: 1.207,18.196) remained as an independent
prognostic factor (Table 6).
Subgroup Analysis of Association between DNMT
Expressions and Clinical Outcome of the Patients
Further analysis was performed with regard to DNMTs
expression in subsets of patients with different clinicopathological
parameters, such as age, menopause state, tumor size, clinical
stage, lymph node metastasis, and location of the tumor. Our data
showed that expression of DNMT1 protein was associated with
improved DFS in patients with larger size of tumors (DFS,
P=0.027; Figure S1). Expression of DNMT1 appeared to be
a protective factor in patients whose tumor occurred in both sides
but it is not statistically significant (OS, P=0.139; Figure S1) (DFS,
P=0.269; Figure S1); opposite of findings from patients whose
tumor occurred in single side (OS, P=0.429; Figure S1) (DFS,
P=0.210; Figure S1). In contrast, DNMT3a protein levels failed
to show any associations with patient survival (P.0.05, Figure S2).
DNMT3b expression was associated with prolonged OS in older
patients (P=0.011; Figure S3), postmenopausal patients
(P=0.019; Figure S3), and patients whose tumor occurred in
both sides (P=0.022; Figure S3). Expression of DNMT3b protein
also marginally associated with prolonged DFS in postmenopausal
patients (P=0.098; Figure S3) and patients whose tumor occurred
in both sides (P=0.097; Figure S3).
Discussion
In the present study, we for the first time immunohistochemi-
cally determined the expression of DNMT1, DNMT3a, and
DNMT3b proteins in benign and malignant ovarian tumor tissues.
The data showed that DNMT3a expression was higher in ovarian
cancer than that in benign tumors, which was consistent with the
previous studies in other types of cancer [15,37,38]. However,
although several previous studies have shown that expression levels
of DNMT3b mRNA [8,9,39,40] and protein [13,40,41] were
increased in a variety of malignant tumors, our current data
demonstrated a lower expression of DNMT3b in ovarian cancer
tissues compared to that of benign tumor. In this study, we also
found that there was no difference in expression of DNMT1
protein between ovarian benign and malignant tissues. It is
agreeable to a previous study reporting that there was no
difference in DNMT1 mRNA expression among normal ovarian
tissue, primary ovarian cancer, and recurrence of ovarian cancer
tissues [33]. Another report demonstrated that expression of
DNMT1 mRNA levels in ovarian cancer HeyA8 and HeyC2 cell
lines was higher than that of normal ovarian epithelial cells [34].
Our current study detected for the first time expression of DNMT
proteins in ovarian cancer by compared to the benign tissues; thus
further study is needed to analyze the altered expression of DNMT
proteins in ovarian cancer with the comparison with normal
ovarian tissues. In any events, due to the complex mechanisms
responsible for regulation of DNMT expressions and functions of
DNMTs in carcinogenesis, the altered expression and effects of
DNMTs should be further investigated in ovarian cancer although
their aberrant expressions were found to be because of methyl-
Figure 1. Immunohistochemical staining of DNMT3a, DNMT3b, and DNMT1 proteins in ovarian cancer tissues. Representative
examples of negative (A, E, I), weakly positive (B, F, J), moderately positive(C, G, K), and strong positive (D, H, L) immunostaining for DNMT3a,
DNMT3b, and DNMT1 expression are shown, respectively; Arrows indicate the field enlarged. Magnification: 6400; enlarged sites: 61000.
doi:10.1371/journal.pone.0040024.g001
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and embryonic tissues [42,43]. However, mutation and loss of
expression of p53 protein led to overexpression of DNMT1 in
leukemia, colorectal cancer and lung cancer [44]. In addition,
microRNAs are also involved in regulation of DNMT expression
[45,46]. Borderline epithelial tumor was a significant and
important group of epithelial tumor of the ovary. We have also
collected borderline epithelial tumors but the number of border-
line tumors available in our study were only 6, so we do not
analyzed the borderline epithelial tumors in this study, and we will
continue to collect more borderline tumors for future study.
Moreover, our current study further associated the relevance of
three DNMT protein expressions with clinicopathological features
from ovarian cancer patients. The data showed that DNMT1
expression was positively correlated with age of the patients, i.e.,
DNMT1 protein was expressed more in older patients, the data of
which were consistent with that of lymphoma [13]. Moreover,
DNMT1 protein was expressed more in post-menopausal patients
than that in pre-menopausal patients. In addition, our data
showed that expression of DNMT1 protein was relevant with the
localization of the tumor. However, to date, we don’t know why
these happened or the implication of these associations. In
addition, we also found that expression of DNMT1 was higher
in the unilateral ovarian cancer than in bilateral ovarian cancer,
which may indicate the difference of the unilateral and bilateral
ovarian cancer in terms of the biological characteristics, genetics,
and mechanism. A previous study has reported that DNMT1
expression was associated with lymph node metastasis in pancreas
cancer [17], but we did not find such an association in ovarian
cancer.
In addition, our current study showed that DNMT3a expression
was associated with histological type, e.g., ovarian serous
carcinoma expressed higher levels of DNMT3a protein. DNMT3a
expression was positively associated with serum CA125 level, while
DNMT3b expression was associated with lymph node metastasis
and serum CA199 level, which is novel and was not report before.
In terms of survival prediction using different DNMT expres-
sions, previous studies showed that overexpression of DNMT1 or
DNMT3b was associated with a poor prognosis in cancers of the
lung [15], liver [18,35], and pancreas [17], lymphoma [13] and
other malignancies. In ovarian cancer, our current study showed
a different trend of DNMT associations with prognosis, i.e., the
overall survival (OS) and disease-free survival (DFS) of ovarian
cancer patients were better with expression of DNMT1 and
DNMT3b proteins compared to the patients without expression of
DNMT1 and DNMT3b proteins. Moreover, co-expression of
Figure 2. Immunohistochemical staining of DNMT3a, DNMT3b, and DNMT1 proteins in benign ovarian tumors. Representative
examples of negative (A, E, I), weakly positive (B, F, J), moderately positive(C, G, K), and strong positive (D, H, L) immunostaining for DNMT3a,
DNMT3b, and DNMT1 expression are shown, respectively. Magnification: 6400.
doi:10.1371/journal.pone.0040024.g002
Table 3. Correlations between DNMTs expression in ovarian
cancers.
DNMT3a DNMT3b
Features n r
a P–value
b r
a P–value
b
DNMT1 142 0.130 0.122 0.195 0.020
DNMT3a 142 0.152 0.071
aSpearman’s coefficient of correlation;
bP-value obtained from Spearman’s correlation.
doi:10.1371/journal.pone.0040024.t003
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with improved OS. Moreover, our additional results showed that
DNMT3a in different subsets of patients with ovarian cancer had
no effect on the survival status, although DNMT1 expression
showed better OS and DFS in patients with large tumors than that
in patient with smaller tumors. The similar is true for DNMT3b
expression in older patients, postmenopausal patients, and patients
with bilateral tumors positive. These completely different data
from the current study suggest different biological characteristics of
ovarian cancer from other cancers. However, future study is
needed to confirm our current finding.
In a variety of cancers, DNMT1, DNMT3a, and DNMT3b
were reported to be highly expressed and associated with poor
prognosis. Hypermethylation of some tumor suppress gene
promoters (TSG) that affect the prognosis can partially explain
the poor prognosis associated with patients with DNMT over-
expression [47,48,49,50], although methylation of most gene
promoters doesn’t have high correlation with the expression of
Table 4. Correlation between DNMTs expression and clinicopathological features of sporadic ovarian cancer patients.
Features n DNMT1 n (%)
aDNMT3a n (%)DNMT3b n (%) DN3a+DN3b n (%) DN1+DN3a n (%) DN1+DN3B N (%)
Age at diagnosis 138
# 53 (year) 79 36(45.6) 53 (67.1) 42 (53.2) 33(41.8) 27(34.2) 23(29.1)
.53 (year) 59 38(64.4) 37 (62.7) 35 (59.3) 25(42.4) 25(42.4) 26(44.1)
P
b 0.028 0.593 0.471 0.944 0.326 0.069
Menopause state 130
Pre- Menopause 45 15(33.3) 29 (64.4) 20(44.4) 18(40.0) 10(22.2) 8(17.8)
Post- Menopause 85 56(65.9) 54 (63.5) 51(60.0) 35(41.2) 39(45.9) 40(47.1)
P 0.000 0.918 0.090 0.897 0.008 0.001
Tumor size(cm) 119
# 5.0 cm 15 7(46.7) 8(53.3) 7(46.7) 3(20.0) 6(40.0) 4(26.7)
5,10 cm 53 32(60.4) 33(62.3) 28(52.8) 19(35.8) 18(34.0) 18(34.0)
.10 cm 51 27(52.9) 33(64.7) 30(58.8) 26(51.0) 19(37.3) 19(37.3)
P 0.571 0.727 0.665 0.066 0.890 0.746
Nodes metastasis 116
no 89 48 (53.9) 59 (66.3) 48 (53.9) 41(46.1) 35(39.3) 31(34.8)
yes 27 14 (51.9) 16 (59.3) 21 (77.8) 12(44.4) 9(33.3) 12(44.4)
P 0.849 0.503 0.027 0.882 0.574 0.365
FIGO stage 127
I,II 31 18 (58.1) 22 (71.0) 18 (58.1) 17(54.8) 12(38.7) 11(35.5)
III,IV 96 51 (53.1) 63 (65.6) 53 (55.2) 39(40.6) 36(37.5) 34(35.4)
P 0.631 0.583 0.781 0.166 0.904 0.995
Histological type 130
serous 110 59 (53.6) 76 (69.1) 64 (58.2) 48(43.6) 45(40.9) 41(37.3)
mucinous 12 7 (58.3) 4 (33.3) 7 (58.3) 6(50.0) 5(41.7) 4(33.3)
clear cell 8 7 (87.5) 4 (50.0) 4 (50.0) 3(37.5) 2(25) 4(50.0)
P 0.200 0.027 0.933 0.853 0.670 0.754
Location of tumor 129
single side 56 38 (67.9) 37 (66.1) 31 (55.4) 23(41.1) 27(48.2) 27(48.2)
both sides 73 33 (45.2) 49 (67.1) 41 (56.2) 32(43.8) 22(30.1) 20(27.4)
P 0.010 0.900 0.927 0.753 0.036 0.015
CA125, U/ml 89
35,500 40 25 (62.5) 22 (55.0) 21 (52.5) 14(35.0) 14(35.0) 15(37.5)
500,1000 32 18 (56.2) 18 (56.2) 14 (43.8) 11(34.4) 11(34.4) 10(31.2)
.1000 17 7 (41.2) 15 (88.2) 9 (52.9) 8(47.1) 8(47.1) 6(35.3)
P 0.332 0.044 0.723 0.638 0.638 0.917
CA199, U/ml 88
0,37 67 30 (44.8) 40 (59.7) 29 (43.3) 25(37.3) 19(28.4) 16(23.9)
.37 21 13 (61.9) 15 (71.4) 14 (66.7) 11(52.4) 9(42.9) 11(52.4)
P 0.171 0.333 0.061 0.220 0.213 0.013
aNumbers in parentheses are percentage.
bP-value obtained from Pearson Chi-Square or Fisher’s exact test.
doi:10.1371/journal.pone.0040024.t004
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some of these DNMTs was associated with better prognosis of
ovarian cancer patients. Previous studies demonstrated that
methylation of DNA CpG island in tumor tissues was not the
only part of the hypermethylation of genes, that hypomethylation
also occurred in some regions of genomic DNA, and that
abnormal hypomethylation in human genome affected prognosis
of patients with prostate cancer, liver cancer, and glioma
[52,53,54]. Like other cancers, ovarian cancer cells also show
a global hypomethylation in the genome and a local hypermethy-
lation of tumor suppressor gene promoters [55]. Two previous
studies used methylation chip as the high-throughput method to
screen gene hypermethylations that may affect the prognosis of
patients with ovarian cancer [56,57] and found that a higher
degree of CpG island methylation is associated with reduced
patient progression-free survival (PFS). While other studies
reported that promoter hypermethylation was involved in DNA
damage repair genes in ovarian cancer and associated with
improved prognosis of patients through increased the sensitivity to
chemotherapy [58,59]. In addition, recent studies showed that
DNMT inhibitor was only able to partially reverse platinum
resistance in patients with ovarian cancer [32]. Another study
evaluated the activity and tolerability of a demethylation agent
fazarabine (Ara-AC) in patients with ovarian cancer, and no
complete or partial responses were observed in the 19 patients
[29]. Taken altogether, our current study indicates that the
mechanism and clinical significance of altered expression of
DNMTs in ovarian cancer could be further evaluated.
Materials and Methods
Tissue Specimens
Tissue samples from 186 patients with ovarian tumors were
recruited from the Department of Surgical Oncology and General
Surgery, China Medical University-Affiliated First and Second
Hospitals between 2002 and 2010. Out of 186 cases, 142 cases
were histologically confirmed as ovarian epithelial carcinoma and
44 cases were benign ovarian tumors. None of our patients had
any family history of cancer. The patients were surgically staged
according to the current FIGO (International Federation of
Gynecologists and Obstetricians classification system). Histological
diagnosis was reached based on the criteria of the World Health
Organization. Our study was attached to another clinical trial
which we obtained informed consent from all participants.
Because this trial was about DNMT inhibitor and we want to
know the clinicopathological significance and prognostic value of
DNMT expressions in sporadic ovarian cancer. So we like to add
this study about DNMT expression. We called to each patient,
Figure 3. Kaplan-Meier estimates of patients with ovarian cancer stratified by DNMTs protein expression. Survival curves show that
although there was no statistical significance, patients with DNMT1 expression had a trend of improved overall survival (A) and disease-free survival
(D) than those with negative expression, and so did DNMT3b (C and F). But there is no significant difference between DNMT3a expression and overall
survival or disease-free survival (B and E). P-value obtained from the log-rank test.
doi:10.1371/journal.pone.0040024.g003
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called, a notary public was present and will give testimony, and we
received the mobile phone short message which we required
participants who consent the study to send to us. Because the time
was limited and some participants were out of the hospital, so it is
difficult to obtain written consent. The Institute Research Medical
Ethics Committee of China Medical University discussed and
approved the consent procedure. Finally, we obtained verbal
consent from 186 patients.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue samples were cut
into 4-mm thick sections and mounted onto poly-L-lysine-coated
glass slides. For immunohistochemical staining, the sections were
deparaffinized in xylene, rehydrated in a series of alcohol, and
washed in the tap water. The sections were then cooked in 10 mM
sodium citrate buffer, pH 6.0, for 10 min in an autoclave for
antigen retrieval. Endogenous peroxidase activity was blocked by
incubating the sections in 3% H2O2 at 37uC for 20 min. after that,
the sections were blocked to avoid nonspecific binding by addition
of a 10% normal goat serum at 37uC for 30 min and then
incubated for 4uC overnight with the polyclonal antibody against
DNMTs (DNMT1, sc-20701, 1:200 dilution; DNMT3a, sc-20703,
1:200 dilution; DNMT3b sc-130740, 1:100 dilution; Santa Cruz
Biotechnology, USA). The specificity of antibodies had been
confirmed by using Western blot analysis (data not shown). In the
next day, the sections were washed five times with 0.01 mol/L
phosphate-buffered saline (PBS; pH 7.4) for 15 min and then
incubated with a biotinylated secondary antibody for 30 min at
37uC in the dark. After that, the sections were incubated with
Figure 4. Kaplan-Meier estimates of patients with ovarian cancer stratified by co-expression of DNMTs. Survival curves show that co-
expression of DNMT1 and DNMT3b was significantly associated with improved overall survival compared to negative samples (P=0.014, Fig. 3E). P-
value obtained from the log-rank test.
doi:10.1371/journal.pone.0040024.g004
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(LSAB kit; Dako, Glostrup, Denmark), washed in PBS, and stained
with DAB (3, 3-diaminobenzidine). Finally, the sections were
counterstained with Mayer’s hematoxylin, dehydrated, and
mounted. Negative controls were run in parallel, and were
generated by PBS replacing the anti-DNMTs antibody.
Evaluation of Immunohistochemistry
The immunostained sections were reviewed and scored in-
dependently by two investigators who were blinded to the patients’
clinicopathological characteristics. The nuclear expressed DNMTs
are the functional type of DNMT proteins; therefore, only nuclear
positivity for the DNMTs proteins was evaluated using semi-
quantitative scoring criteria according to the staining intensity (0,
negative; 1, weak; 2, moderate; and 3, severe) and proportion of
positive cells (0, negative; 1, positive in #10%; 2, positive in
.10% and #50%; 3, positive in .50% and #80%; 4, positive in
.80% of tumor cells). The two scores were multiplied for each
case and the expression was graded as: negative, score=0; weak
Table 5. Univariate Cox regression analysis of clinical and pathological data correlated with OS and DFS in total ovarian cancers.
Factor Overall survival Disease-free survival
nR R
a 95%CI
b P RR 95%CI P
Age, years 85 1.283 0.638,2.583 0.485 1.330 0.724,2.442 0.357
.53/#53
Menopause state 83 1.187 0.532,2.649 0.676 1.335 0.668,2.667 0.413
post/pre
Tumor size, cm 70 0.277 0.102,0.752 0.012 0.373 0.171,0.812 0.013
.10/#10.0
Nodes metastasis 68 1.695 0.708,4.055 0.236 1.114 0.483,2.571 0.799
yes/no
Histological type 84 0.950 0.411,2.197 0.904 0.886 0.423,1.853 0.748
serousr/non-serous
FIGO stage 79 8.750 2.072,36.951 0.003 7.446 2.279,24.331 0.001
III,IV/I,II
Location of neoplasia 78 2.019 0.931,4.376 0.075 2.227 1.112,4.462 0.024
both sides/single side
CA125, U/ml 56 1.688 0.884,3.224 0.113 2.067 1.218,3.508 0.007
.1000/500,1000/35,500
CA199, U/ml 53 0.366 0.085,1.579 0.178 0.399 0.119,1.342 0.138
.37/0,37
DNMT1 stutas 85 0.525 0.260,1.062 0.073 0.640 0.347,1.178 0.152
positive/negative
DNMT3a stutas 85 0.875 0.437,1.754 0.708 0.867 0.470,1.601 0.649
positive/negative
DNMT3b stutas 85 0.583 0.291,1.167 0.128 0.786 0.425,1.453 0.442
positive/negative
aRR, relative risk;
b95% CI, 95% confidence interval.
doi:10.1371/journal.pone.0040024.t005
Table 6. Multivariate Cox Regression analysis of OS and DFS in ovarian cancers.
Overall survival Disease-free survival
Category RR
a (95% CI
b) P RR (95% CI) P
Clinicalstage (III,IV/I,II) 6.977 (1.322,36.822) 0.022 4.686 (1.207,18.196) 0.026
Tumor size,cm (.10/#10.0) 0.566 (0.188,1.706) 0.312 0.546 (0.226,1.322) 0.180
Location of neoplasia (both/single side) 0.581 (0.195,1.732) 0.330 0.943 (0.363,2.452) 0.904
DN1+DN3b (positive/negative) 0.493 (0.170,1.429) 0.193 0.689 (0.286,1.659) 0.406
aRR, relative risk;
b95% CI, 95% confidence interval.
doi:10.1371/journal.pone.0040024.t006
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strong expression, score=9–12.
Statistical Analysis
Comparison of DNMT expression scores between samples was
analyzed by using the Mann-Whitney U-test. Spearman rank
correlation test was performed to analyze the association between
DNMT expressions. Correlations between clinicopathological
factors and DNMTs expression were analyzed by using the Chi-
square (X
2) test or Fisher’s Exact Probability Test. Survival of the
patients according to DNMT expressions was analyzed by using
Kaplan–Meier curve analysis with the log-rank test. Cox re-
gression analysis was used for the multivariate analysis. Statistical
significance was defined as P,0.05. All statistical tests were carried
out by using the SPSS software package (SPSS 11.5 Inc, Chicago,
IL, USA).
Supporting Information
Figure S1 Kaplan-Meier survival analysis of association
between DNMT1 expression and OS and DFS in
different subgroups.
(TIF)
Figure S2 Kaplan-Meier survival analysis of association
between DNMT3a expression and OS and DFS in
different subgroups.
(TIF)
Figure S3 Kaplan-Meier survival analysis of association
between DNMT3b expression and OS and DFS in
different subgroups.
(TIF)
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